Digitally created image of brain in skull



FTD and MND research group

ForeFront is a collaborative research group in Australia dedicated to the study of frontotemporal dementia (FTD) and motor neurone disease (MND).

FTD and MND are a group of disorders identified by distinct clinical signs and symptoms, and/or specific brain pathologies. These disorders are generally rapidly progressing, cause behavioural, language or motor deficits (often in combination), and together are a leading cause of dementia, particularly in people under 65 years of age.

ForeFront is an amalgamate of two government funded research groups:

Frontotemporal dementia and motor neurodegenerative syndromes
This National Health and Medical Research Council (NHMRC) program brings together a team of internationally recognised leaders in clinical, pathological and biological research on FTD and motor neurodegenerative syndromes. Individually these team leaders, along with their research staff, have made significant advances in these diseases, and this program will unify their efforts and focus on translating findings into better clinical information and intervention studies.

Learn more…

Memory node of the ARC Centre of Excellence in Cognition and its Disorders This program investigates the cognitive systems and brain structures underlying various forms of memory, including autobiographical memory, episodic memory and semantic memory. The program uses experimental neuropsychological methods, as well as structural and functional brain imaging in patients with progressive brain pathologies such as frontotemporal dementia. Despite sustained research interest spanning 50 years, the cognitive and neural architecture of episodic and semantic memory systems and the factors that affect their optimal functions are still not fully understood.

See what’s going on at NeuRA


LEAD!- Leveraging Evidence into Action on Dementia

Currently, there is no effective treatment for dementia, highlighting the urgent need to preventing more cases through evidence-based strategies for risk reduction. As there is an overlap between the risk factors for dementia and other preventable non-communicable diseases including stroke, diabetes, and heart disease, it is important to build upon proven risk-reduction strategies. What is LEAD? LEAD! is a project funded by the NHMRC Boosting Dementia Research Grant led by Professor Kaarin Anstey. It involves an international collaboration between leading academics, clinicians, consumers, and community members. Organisations involved include the Department of Health, WHO, Dementia Australia, Alzheimer’s Disease International, Diabetes Australia, and Heart Foundation. The project aims to translate dementia research and implement evidence-based strategies for dementia risk reduction to individuals, communities, and healthcare centres. Three workstreams The project has three concurrent workstreams over five years: Development, Implementation, and Evaluation and adoption. The Development stream, led by Professor Kaarin Anstey and Associate Professor Peters, focuses on building a new tool for predicting dementia and other non-communicable diseases including stroke, diabetes or myocardial infarction. The tool will be available to the public, researchers and clinicians. It will save clinical assessment time, accurately predict multiple outcomes and will be more acceptable in comparison to using individual tools for each disease outcome. The Implementation stream led by Professor Nicola Lautenschalger’s team at the University of Melbourne, will develop strategies to support the implementation of dementia risk reduction evidence by engaging with consumers, clinicians, policy makers, and the public. The stream will develop strategies for incorporating the new risk assessment tool into various technological platforms (e.g., websites or apps). The Evaluation and adoption stream, led by Professor Anstey and in collaboration with Professor Louisa Jorm and Dr Heidi Welberry at UNSW, focuses on measuring trajectories of Australian’s national risk factor profiles for multiple chronic diseases. Collaboration with key stakeholders including the WHO will help build an evaluation framework and methodology for implementing evidence on dementia risk reduction based on WHO guidelines at national level and in the global context.